This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Module 4: Selecting a Biologic in UC: Practical Considerations

Module 4: Selecting a Biologic in UC: Practical Considerations

Format

Clinical Review

Time to Complete

30 minutes

Released

November 30, 2017

Expires

November 30, 2018
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / CNE Contact Hour(s)

Accredited Provider

Jointly provided by Postgraduate Institute for Medicine and Strategic Consultants International

Commercial Supporter

Supported by an educational grant from Takeda Pharmaceuticals, U.S.A. Inc

Program Description

When devising a treatment plan for patients with UC, a number of practical factors should be considered when selecting an appropriate biologic therapy. In this module, the basis for the individualization of biologic therapy among heterogeneous UC patients is described. Practical considerations which may influence choice of therapy including routes of administration and the criteria for payer reimbursement are summarized, along with other non-clinical factors which may influence choice of biologic.

Intended Audience

Physicians and registered nurses

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain how individualized management should include agreed treatment goals and a treat-to-target approach but also consider patient history, disease factors, and patient preference
  • Discuss additional, non-medical factors which may influence patients’ choice of biologic therapy such as route of administration and payer reimbursement
  • Describe how ongoing monitoring of therapy can provide a guide for future treatment plans
  • Summarize how extraintestinal manifestations of IBD and co-morbid diseases may influence choice of biologic therapy

Accreditor Disclosure of Conflicts of Interest Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported any financial relationships or relationships to products or devices they or their spouse/life partner with commercial interests related to the content of this CME activity under the Faculty section below.

Faculty

Course Author
David Rubin, MD

Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine

Dr. Rubin discloses the following:
Consulting fees: Abbvie, Abgenomics, Allergan Inc., Amgen, Celgene Corporation, Forward Pharma, Genentech/Roche, Janssen Pharmaceuticals, Merke & Co. Inc., Miraca Life Sciences, Napo Pharmaceuticals, Pfizer, Salix Pharmaceuticals Inc., Samsung Bioepis, Sandoz Pharmaceuticals, Shire, Takeda
Contracted research: Abbvie, Greentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, Takeda,
UCB Pharma
Other associations: American College of Gastroenterology (Board of Trustees), Cornerstones Health Inc. (Co-Founder), GoDuRn, LLC (Co-Founder)

Course Director
Miguel D. Regueiro, MD

IBD Clinical Medical Director
Division of Gastroenterology, Hepatology and Nutrition
Department of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Dr. Regueiro discloses the following:
Consulting Fees: Abbvie, Takeda, Amgen, Janssen, Pfizer, UCB

Joint Provider Disclosures

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, have nothing to disclose. The SCI planners and managers, Ian Morgan MSc, Elena Urso BSc, and Eoin Duffy, PhD, have nothing to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CNE Contact Hour(s)

Accreditation Statement

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This educational activity for 0.50 contact hour(s) is provided by the Postgraduate Institute for Medicine.

Disclosure of Unlabeled Use

This education activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, a review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine AT (303) 799-1930 and via email at inquires@pimed.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue


Related to this activity